Key Highlights

  • Net loss was USD 7.0 million, or USD 1.76 per share, versus USD 2.56 estimated.
  • General and administrative expense rose to USD 3.9 million from USD 2.6 million.
  • Research and development expense eased to USD 3.0 million from USD 3.1 million.
  • Cash was USD 144,713 at September 30, 2026.

Loss Widens on Administrative Costs

Tevogen Inc. (NASDAQ:TVGN) reported a third-quarter net loss of USD 7,003,801 versus USD 5,726,812. Net loss attributable to common stockholders was USD 7,197,006 versus USD 5,862,428, or USD 1.76 per share versus USD 1.50, compared with an estimated loss of USD 2.56 per share.

General and administrative expense rose to USD 3,939,612 from USD 2,618,679, while Research and Development expense eased to USD 2,962,709 from USD 3,110,752. Total operating expenses were USD 6,902,321 versus USD 5,729,431, and interest expense, net, was USD 99,950 versus USD 62,340.

The change in Fair Value of warrants was a loss of USD 1,530 versus a gain of USD 64,959 in the quarter and a gain of USD 23,124 versus USD 57,406 for the nine months.

Weighted average shares were 4,097,711 versus 3,920,576.

Nine-Month Results

For the nine months, net loss was USD 18,211,996 versus USD 21,597,852. Research and development was USD 9,380,076 versus USD 9,005,811, general and administrative expense was USD 8,585,541 versus USD 12,524,503 and total operating expenses were USD 17,965,617 versus USD 21,530,314.

Weighted average common stock outstanding was 4,097,711 for the quarter versus 3,920,576.

Interest expense, net, was USD 269,503 for the nine months versus USD 124,944.

Business Lines

The company describes itself as a "healthcare company focused on addressing unmet needs" across biotechnology, technology and healthcare services. Tevogen Bio develops off-the-shelf cellular immunotherapies, Tevogen.AI applies artificial intelligence and Data Analytics to precision medicine, and the company recently established Tevogen Healthcare Services.

The company says it is harnessing CD8+ cytotoxic T lymphocytes to develop off-the-shelf therapies, and describes its healthcare services initiative as intended to support longer-term efforts to improve healthcare affordability, accessibility and efficiency.

Cash and Liabilities

Cash was USD 144,713 versus USD 552,372 at December 31, 2025, and total current Assets were USD 841,136 versus USD 1,539,783. Total liabilities were USD 14,807,972 versus USD 12,617,720, and the Balance Sheet shows a stockholders' deficit.

Net cash used in Operating Activities for the nine months was USD 7,694,336 versus USD 10,147,310, with proceeds of USD 3,000,000 from a Loan agreement and USD 2,967,000 from pre-funded warrants, net of offering costs.

Prepaid expenses and other assets were USD 537,604 versus USD 828,592 and an amount due from a related party was USD 158,819.

The balance sheet shows a total stockholders' Deficit of USD 11,293,602 versus USD 8,234,726 at December 31, 2025, an accumulated deficit of USD 158,654,545 versus USD 139,660,549 and total assets of USD 3,514,370 versus USD 4,382,994. Accounts Payable were USD 2,958,013 versus USD 3,340,127 and total current liabilities were USD 6,371,539 versus USD 7,068,491.

The loan agreement balance rose to USD 7,400,000 from USD 4,400,000, and notes payable were USD 1,651,000 at both dates.

Accrued expenses and other liabilities were USD 1,184,786 versus USD 1,499,624, noncurrent operating Lease liabilities were USD 1,033,078 versus USD 1,122,750 and derivative Warrant liabilities were USD 3,355 versus USD 26,479.